top of page

Sarvnaz Sadrameli

PharmD

Rotations

Cellular Therapy, Multiple Myeloma, Lymphoma, Supportive Care/Medical Oncology

Education

PharmD: University of Texas at Austin

Residency Training

PGY1: University of Illinois at Chicago
PGY2 Oncology: University of Wisconsin Hospitals and Clinics (UW Health - Madison)

Sarvnaz Sadrameli

Practice Interests

Cellular therapy, graft-versus-host disease

Professional Affiliation

  • Hematology/Oncology Pharmacy Association (HOPA)

  • American Society of Health-System Pharmacists (ASHP)

  • American Society for Transplantation and Cellular Therapy (ASTCT)

Recent Publications

  • Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM. Authors; Reply to Bonnet et al.; Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update�. Drugs. 2021;81(5):615-7.

  • Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs. 2021;81(1):125-56.

Academic and/or National Presentations

Current Research

  • Tyrosine kinase inhibitors tolerability assessment in patients with advanced solid tumor malignancies and hypoalbuminemia

bottom of page